Case 5, who continued hormonal therapy (i.e. tamoxifen) for an additional 22 months, terminated anti-HER2 therapy after testing negative for ERBB2 related genes on liquid biopsy.Conclusions:This observational study suggests that in stage 4 HER2 positive primary breast cancer patients in which cCR...
[14] Hua X, Bi XW, Zhao JL, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022 Feb 15;28(4):637-645....
[5] Wong Y, Raghavendra AS, Hatzis C, et al. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist. 2019;24(3):313-318. doi:10.1634/theoncologist.2018-0213 [6] Sandra M Swain, et al. Pe...
[6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer.N Engl J Med.2015 Jan 8;372(2):134-41. [7]MDACC.Breast cancer–invasive stage I-III algorithm.https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians...
参考文献: Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9...
Abramson V.G., Arteaga C.L., Spring L.M., Waks A.G., et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021;11:2474–2487. doi: 10.1158/2159-8290...
[1]Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest (2010) 28(9):9...
[20].Bartsch R, Berghoff AS, Furtner J, Bergen ES, Roider-Schur S, Marhold M, et al.Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: results ...
[17]Ismael G, Hegg R, et al.Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. ...
Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. ...